1.15
price up icon6.48%   0.07
after-market Dopo l'orario di chiusura: 1.18 0.03 +2.61%
loading

Perché le azioni Aclaris Therapeutics Inc (ACRS) sono in ribasso?

Abbiamo notato un calo di 10.74% nelle azioni di Aclaris Therapeutics Inc (ACRS) durante la sessione di negoziazione di 2025-04-10. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

  • Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
  • Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.
diagnostics_research DGX
$163.99
price up icon 0.09%
diagnostics_research LH
$221.46
price up icon 1.30%
diagnostics_research WAT
$325.22
price up icon 3.36%
$148.04
price up icon 3.32%
diagnostics_research MTD
$1,041.90
price up icon 4.43%
diagnostics_research IQV
$145.55
price up icon 1.63%
Capitalizzazione:     |  Volume (24 ore):